MedPath

Multicenter Retrospective Study to Evaluate Necitumumab plus Cisplatin/Gemcitabine after Immune-check-point inhibitors in Advanced Squamous-Cell Lung Cancer in Japan (NINJA study)

Not Applicable
Recruiting
Conditions
advanced metastatic or recurrent Squamous-cell lung cancer
Registration Number
JPRN-UMIN000048656
Lead Sponsor
Teikyo University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who received GCN therapy after 5th line Patients who participated in NESSIE trial (jRCTs051200138)

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath